WO2001045691A3 - Method of treating gastrointestinal tract disease with purinergic receptor agonists - Google Patents

Method of treating gastrointestinal tract disease with purinergic receptor agonists Download PDF

Info

Publication number
WO2001045691A3
WO2001045691A3 PCT/US2000/035439 US0035439W WO0145691A3 WO 2001045691 A3 WO2001045691 A3 WO 2001045691A3 US 0035439 W US0035439 W US 0035439W WO 0145691 A3 WO0145691 A3 WO 0145691A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastrointestinal tract
diphosphate
triphosphate
gastrointestinal
provides
Prior art date
Application number
PCT/US2000/035439
Other languages
French (fr)
Other versions
WO2001045691A2 (en
Inventor
Benjamin R Yerxa
Janet L Rideout
William Pendergast
Sammy R Shaver
Zhen Zhang
Ward M Peterson
Mathew Cowlen
Original Assignee
Inspire Pharmaceuticals Inc
Benjamin R Yerxa
Janet L Rideout
William Pendergast
Sammy R Shaver
Zhen Zhang
Ward M Peterson
Mathew Cowlen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc, Benjamin R Yerxa, Janet L Rideout, William Pendergast, Sammy R Shaver, Zhen Zhang, Ward M Peterson, Mathew Cowlen filed Critical Inspire Pharmaceuticals Inc
Priority to MXPA02005161A priority Critical patent/MXPA02005161A/en
Priority to AU26031/01A priority patent/AU2603101A/en
Priority to BR0016021-0A priority patent/BR0016021A/en
Priority to CA002395108A priority patent/CA2395108A1/en
Priority to JP2001546630A priority patent/JP2003524636A/en
Priority to EP00989533A priority patent/EP1261323A2/en
Priority to KR1020027007963A priority patent/KR20020069218A/en
Publication of WO2001045691A2 publication Critical patent/WO2001045691A2/en
Publication of WO2001045691A3 publication Critical patent/WO2001045691A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a method of regulating water and mucin secretions and fluid transport in the gastrointestinal tract. The invention also provides a method for treating a gastrointestinal disease in which the mucosal barrier of the gastrointestinal system is impaired. The invention additionally provides a method for correcting disorders of fluid secretion or absorption in the gastrointestinal system. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor agonist, in an amount effective to regulate water and mucin secretions or to correct abnormal fluid transport in the gastrointestinal tract. The pharmaceutical composition used in this invention comprises a P2Y purinergic receptor agonist such as uridine 5'-diphosphate (UDP), uridine 5'-triphosphate (UTP), cytidine 5'-diphosphate (CDP), cytidine 5'-triphosphate (CTP), adenosine 5'-diphosphate (ADP), adenosine 5'-triphosphate (ATP), and their analogs; and dinucleotide polyphosphate compounds of general Formula (IV). Said compound is prepared in an oral form, an injectable form, or a suppository form, and administered to a patient.
PCT/US2000/035439 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists WO2001045691A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA02005161A MXPA02005161A (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists.
AU26031/01A AU2603101A (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists
BR0016021-0A BR0016021A (en) 1999-12-22 2000-12-22 Process of treating gastrointestinal tract diseases with purinergic receptor agonists
CA002395108A CA2395108A1 (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists
JP2001546630A JP2003524636A (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract with purinergic receptor agonist
EP00989533A EP1261323A2 (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists
KR1020027007963A KR20020069218A (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17171099P 1999-12-22 1999-12-22
US60/171,710 1999-12-22

Publications (2)

Publication Number Publication Date
WO2001045691A2 WO2001045691A2 (en) 2001-06-28
WO2001045691A3 true WO2001045691A3 (en) 2002-04-18

Family

ID=22624842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035439 WO2001045691A2 (en) 1999-12-22 2000-12-22 Method of treating gastrointestinal tract disease with purinergic receptor agonists

Country Status (9)

Country Link
EP (1) EP1261323A2 (en)
JP (1) JP2003524636A (en)
KR (1) KR20020069218A (en)
CN (1) CN1413113A (en)
AU (1) AU2603101A (en)
BR (1) BR0016021A (en)
CA (1) CA2395108A1 (en)
MX (1) MXPA02005161A (en)
WO (1) WO2001045691A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
WO2003039473A2 (en) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US6683060B2 (en) * 2002-02-25 2004-01-27 Advanced Gene Technology Corp. Matrix metalloproteinase and tumor necrosis factor inhibitors
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
GB0312844D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of compounds in medicine
JP5092400B2 (en) * 2004-06-28 2012-12-05 味の素株式会社 Nutritional composition and composition for preventing or improving digestive tract function deterioration
BRPI0515413B8 (en) * 2004-09-17 2021-05-25 Ajinomoto Kk use of a glutamic acid salt with basic amino acid
JP5408882B2 (en) * 2008-01-23 2014-02-05 ヤマサ醤油株式会社 Salivary secretion promoter
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010287A1 (en) * 1993-10-15 1995-04-20 Wisconsin Alumni Research Foundation Substituted purine nucleoside analogs and method for treating endotoxin shock
WO1998034942A2 (en) * 1997-02-06 1998-08-13 Inspire Pharmaceuticals, Inc. Dinucleotides and their use
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
WO2000050024A2 (en) * 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010287A1 (en) * 1993-10-15 1995-04-20 Wisconsin Alumni Research Foundation Substituted purine nucleoside analogs and method for treating endotoxin shock
WO1998034942A2 (en) * 1997-02-06 1998-08-13 Inspire Pharmaceuticals, Inc. Dinucleotides and their use
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
WO2000050024A2 (en) * 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OTA SHINICHI ET AL: "P-2 purinergic receptor regulation of mucus glycoprotein secretion by rabbit gastric mucous cells in a primary culture.", GASTROENTEROLOGY, vol. 106, no. 6, 1994, pages 1485 - 1492, XP001037169, ISSN: 0016-5085 *
ROMAN R.M. ET AL: "Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function.", GASTROENTEROLOGY, (1999) 116/4 (964-979), XP002185773 *

Also Published As

Publication number Publication date
AU2603101A (en) 2001-07-03
EP1261323A2 (en) 2002-12-04
BR0016021A (en) 2003-07-15
CN1413113A (en) 2003-04-23
MXPA02005161A (en) 2002-12-09
JP2003524636A (en) 2003-08-19
CA2395108A1 (en) 2001-06-28
WO2001045691A2 (en) 2001-06-28
KR20020069218A (en) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2001045691A3 (en) Method of treating gastrointestinal tract disease with purinergic receptor agonists
US5763447A (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
CA1302263C (en) Therapeutic nucleosides
KR100606131B1 (en) Dinucleotides and their use
MY120023A (en) Method of treating dry eye disease with uridine triphosphates and related compounds.
ES2531928T3 (en) Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CN100528173C (en) 4'-substituted nucleosides
MXPA01008547A (en) Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof.
HK1028613A1 (en) Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof.
US20040235761A1 (en) Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
NZ313864A (en) Method of obtaining a mucous sample from the lung using triphosphate compounds
WO2000030629A3 (en) Method of promoting cervical and vaginal secretions
KR960703605A (en) METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION
BR0110418A (en) Method for treatment of retinal degeneration with purinergic receptor agonists
JP2005508297A5 (en)
US20020103158A1 (en) Dinucleoside polyphosphate compositions and their therapeutic use as purinergic receptor agonists
DE69031340D1 (en) ANTIVIRAL COMPOSITIONS CONTAINING 3'-AZIDO-2 ', 3'-DIDEOXY-5-METHYLCYTIDINE
KR20050043761A (en) Method for treating or preventing inflammatory diseases
KR900701279A (en) Therapeutic Use of 2 ', 5'-oligoadenylate Derivatives
JP2004043371A (en) New pyrazine derivative, its salt and antiviral agent containing the same
CN102317300B (en) Methods of making nucleoside tetraphosphate analogs
EP1786441A2 (en) Method and means for enhanced pulmonary drug delivery
DE60020891T2 (en) ARYL PHOSPHATE DERIVATIVES OF D4T
BR112019022470A2 (en) COMPOUND, COMPOSITION, AND, METHOD FOR TREATING AN INDIVIDUAL WITH CANCER.
US4044122A (en) Method of treating herpes virus hominis infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005161

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2395108

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027007963

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008176078

Country of ref document: CN

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 546630

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 26031/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000989533

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027007963

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000989533

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000989533

Country of ref document: EP